<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS109236</article-id>
<article-id pub-id-type="doi">10.1101/2020.12.23.424171</article-id>
<article-id pub-id-type="archive">PPR257908</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A SARS-CoV-2 spike binding DNA aptamer that inhibits pseudovirus infection in vitro by an RBD independent mechanism</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Schmitz</surname>
<given-names>Anton</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Weber</surname>
<given-names>Anna</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bayin</surname>
<given-names>Mehtap</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Breuers</surname>
<given-names>Stefan</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fieberg</surname>
<given-names>Volkmar</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Famulok</surname>
<given-names>Michael</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mayer</surname>
<given-names>Günter</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Life and Medical Sciences (LIMES), University of Bonn, Gerhard-Domagk-Str.1, Germany</aff>
<aff id="A2">
<label>2</label>Max Planck Fellow Chemical Biology, Center of Advanced European Studies and Research (caesar), Ludwig-Erhard-Allee 2, Bonn 53175, Germany</aff>
<aff id="A3">
<label>3</label>Center of Aptamer Research &amp; Development, University of Bonn, Gerhard-Domagk-Str. 1, 53121 Bonn, Germany</aff>
<author-notes>
<corresp id="CR1">
<label>*</label>Corresponding authors: <email>gmayer@uni-bonn.de</email>, <email>m.famulok@uni-bonn.de</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>26</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="preprint">
<day>25</day>
<month>12</month>
<year>2020</year>
</pub-date>
<permissions>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">The receptor binding domain (RBD) of the spike glycoprotein of the coronavirus SARS-CoV-2 (CoV2-S) binds to the human angiotensin converting enzyme 2 (ACE2) representing the initial contact point for leveraging the infection cascade. We used an automated selection process and identified an aptamer that specifically interacts with CoV2-S. The aptamer does not bind to the RBD of CoV2-S and does not block the interaction of CoV2-S with ACE2. Notwithstanding, infection studies revealed potent and specific inhibition of pseudoviral infection by the aptamer. The present study opens up new vistas in developing SARS-CoV2 infection inhibitors, independent of blocking the ACE2 interaction of the virus and harnesses aptamers as potential drug candidates and tools to disentangle hitherto inaccessible infection modalities, which is of particular interest in light of the increasing number of escape mutants that are currently being reported.</p>
</abstract>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P2">The coronavirus SARS-CoV-2 binds via its spike protein (CoV2-S) to the extracellular domain of the human angiotensin-converting enzyme 2 (ACE2) initiating the entry process into target cells. CoV2-S is a trimeric, highly glycosylated class I fusion protein. It binds to ACE2 via the receptor binding domain (RBD) of its S1 subunit.<sup>
<xref rid="R1" ref-type="bibr">1</xref>
</sup> The trimeric spike exists in a closed form which does not interact with ACE2 and in an open form where one RBD is in the so-called ‘up' conformation exposing the ACE2 binding site.<sup>
<xref rid="R2" ref-type="bibr">2</xref>
</sup>,<sup>
<xref rid="R3" ref-type="bibr">3</xref>
</sup> Upon RBD binding to ACE2 the interaction between the S1 and S2 subunits is weakened allowing S2 to undergo substantial structural rearrangements to finally fuse the virus with the host cell membrane.<sup>
<xref rid="R2" ref-type="bibr">2</xref>,</sup>
<sup>
<xref ref-type="bibr" rid="R3">3</xref>
</sup> The important role of the RBD for viral infectivity is underlined by the analyses of neutralizing antibodies from sera of human re-convalescents, which reveal binding of these antibodies to RBD.<sup>
<xref rid="R4" ref-type="bibr">4</xref>,</sup>
<sup>
<xref rid="R5" ref-type="bibr">5</xref>
</sup> Consequently, almost all published neutralizing antibodies developed for therapeutic use target RBD, including humanized monoclonal antibodies<sup>
<xref rid="R6" ref-type="bibr">6</xref>
</sup>, antibodies cloned from human B cells<sup>
<xref rid="R7" ref-type="bibr">7</xref>-</sup>
<sup>
<xref rid="R9" ref-type="bibr">9</xref>
</sup> and single-chain camelid antibodies.<sup>
<xref rid="R10" ref-type="bibr">10</xref>,</sup>
<sup>
<xref rid="R11" ref-type="bibr">11</xref>
</sup> However, mutations in RBD of CoV2-S can cause RBD-targeted antibodies ineffectual while the virus's interaction with ACE2 remains unchanged or even found improved.<sup>
<xref rid="R12" ref-type="bibr">12</xref>
</sup> To address this limitation, additional inhibitors of viral infection and a different mode of action, e.g., by targeting other domains of CoV2-S are highly desired but of limited availability.</p>
<p id="P3">Against this backdrop, we here report on a DNA aptamer with a different modality of inhibiting viral infection. As the aptamer does not interact with RBD, it does not interfere with the binding of CoV2-S to ACE2. Regardless, the aptamer inhibits viral infection, exemplified by employing a CoV2-S pseudotyped virus and an ACE2 expressing cell line. These findings demonstrate that viral infection can be inhibited independent of targeting RBD and suggest that inhibition could be possible despite the virus has already bound to cells. The results open the path to inhibitors of SARS-CoV-2 infection with hitherto inaccessible modes of action.</p>
</sec>
<sec id="S2" sec-type="results">
<title>Results</title>
<sec id="S3">
<title>Selection and characterization of CoV2-S binding aptamers</title>
<p id="P4">To identify single-stranded (ss)DNA aptamers that bind to CoV2-S we employed an automated selection procedure<sup>
<xref rid="R13" ref-type="bibr">13</xref>
</sup>. The trimerized His-tagged extracellular domain of CoV2-S, stabilized in the prefusion conformation, was expressed and purified from HEK293 cells<sup>
<xref rid="R14" ref-type="bibr">14</xref>,</sup>
<sup>
<xref ref-type="bibr" rid="R15">15</xref>
</sup> and immobilized for the selection on magnetic beads. After twelve selection cycles (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 1a</xref>
</bold>) the enriched ssDNA libraries were analyzed for improved CoV2-S binding by flow cytometry using cy5-labelled ssDNA and CoV2-S immobilized on magnetic particles (<bold>
<xref ref-type="fig" rid="F1">Fig. 1a</xref>
</bold>). These experiments revealed an increased fluorescence signal of the ssDNA from selection cycle 12 in the presence of CoV2-S (<bold>
<xref ref-type="fig" rid="F1">Fig. 1a</xref>
</bold>). No interaction was observed when particles without CoV2-S or particles modified with His6-Erk2 or His6-dectin-1 were used, indicating specificity of the enriched ssDNA library. In contrast, the ssDNA library from selection cycle 1 did not show interaction with the particles, independent of their modification state (<bold>
<xref ref-type="fig" rid="F1">Fig. 1a</xref>
</bold>). The enriched DNA populations were subjected to next-generation sequencing (NGS), in which 10<sup>
<xref rid="R6" ref-type="bibr">6</xref>
</sup> to10<sup>7</sup> sequences were analyzed per selection cycle (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 1b</xref>
</bold>). This analysis revealed a strong decrease in the number of unique DNA sequences, starting from selection cycle 4 and levelling between 10% to 5% of unique DNA sequences in selection cycle 7 to 12 (<bold>
<xref ref-type="fig" rid="F1">Fig. 1b</xref>
</bold>). Likewise, the distribution of nucleotides within the initial random region changed significantly throughout the course of selection, in which guanine is the most frequently enriched nucleotide (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 1c</xref>
</bold>). These data reveal a strong enrichment of DNA sequences, which is further supported by the occurrence of sequences with high copy numbers, e.g., &gt; 100.000 per sequence starting from the DNA populations from selection cycle 5 onwards (<bold>
<xref ref-type="fig" rid="F1">Fig. 1c</xref>
</bold>). Further in-depth population analysis revealed the occurrence of sequence families, termed family 8, 13, 22, 29, and 30 (<bold>
<xref ref-type="fig" rid="F1">Fig. 1d</xref>
</bold>, <bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 1d</xref>
</bold>, <bold>Supporting Table 1</bold>). Whereas the frequency of sequences belonging to family 8 started to enrich from cycle 8 onwards, all other families were observed in the DNA populations from selection cycles 4 to 6, having maximum frequency between selection cycles 7 to 10 and declined afterwards (<bold>
<xref ref-type="fig" rid="F1">Fig. 1d</xref>
</bold>). We chose representative monoclonal sequences within each family that reflect the enrichment patterns (SP1-7, <bold>
<xref ref-type="fig" rid="F1">Fig. 1e</xref>
</bold>) and tested them regarding interaction with CoV2-S using flow cytometry. These studies revealed interaction of the family 8 sequences SP5, SP6, SP7 with CoV2-S (<bold>
<xref ref-type="fig" rid="F1">Fig. 1f,g</xref>
</bold>). All other sequences and a scrambled version of SP5 (SP5sc) as putative non-binding negative control sequence did not interact with the target protein (<bold>
<xref ref-type="fig" rid="F1">Fig. 1f</xref>
</bold>). SP5, SP6, and SP7 bind with high specificity to CoV2-S; no binding to the isolated RBD, ACE2 or to the spike protein of SARS-CoV (CoV-S) was observed (<bold>
<xref ref-type="fig" rid="F1">Fig. 1h</xref>
</bold>). Kinetic analysis by surface plasmon resonance (SPR) of the interaction of CoV2-S with 5’-biotinylated aptamer variants immobilized on streptavidin coated sensor surfaces show high affinity binding to CoV2-S, with dissociation constants (K<sub>D</sub>) between 9 and 21 nanomolar (<bold>
<xref rid="T1" ref-type="table">Tab. 1</xref>
</bold>, <bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 2a</xref>,<xref ref-type="supplementary-material" rid="SD1">b</xref>
</bold>). All aptamers revealed comparable <italic>K<sub>D</sub>
</italic> values at 37°C vs. 25°C (<bold>
<xref rid="T1" ref-type="table">Tab. 1</xref>
</bold>). A qualitative assay<sup>
<xref rid="R16" ref-type="bibr">16</xref>
</sup> to determine the impact of the 5’-modifications on the aptamers CoV2-S binding properties revealed only minor influence of the 5’-cy5-, 5’-biotin-, or 5’-hydroxyl labels (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 2c</xref>
</bold>). SP5 showed a slightly decreased binding in the hydroxyl state whereas binding of SP6 to CoV2-S was found to increase by ~50% in the unmodified state as compared to the 5’-cy5-modified version (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 2c</xref>
</bold>). The interaction properties of SP7 appeared to be independent of 5’-modifications (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 2c</xref>
</bold>).</p>
<p id="P5">SP6 as a representative of the family 8 was chosen for further analysis (<bold>
<xref ref-type="fig" rid="F1">Fig. 1g</xref>
</bold>). Based on secondary structure predictions (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 2d</xref>
</bold>), the aptamer was initially truncated, yielding SP6.51, and analyzed by flow cytometry for CoV2-S binding. Interestingly, SP6.51 showed strongly improved binding compared to the parental SP6 aptamer (<bold>
<xref ref-type="fig" rid="F1">Fig. 1i</xref>
</bold>). Further truncation of SP6, yielding variants with 45 nucleotides (nt, SP6.45), 41 nt (SP6.41), or 34 nt (SP6.34) maintained the elevated binding properties. When SP6 was truncated to 30 nt (SP6.30) binding fell back to the level of the original SP6 aptamer whereas the interaction with CoV2-S was entirely lost by removing additional 11nt (SP6.19, <bold>
<xref ref-type="fig" rid="F1">Fig. 1i</xref>
</bold>, <bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 2d</xref>
</bold>). Moreover, based on the secondary structure prediction of SP6.34, we investigated the interaction of the point mutants of the minimal aptamer variant SP6.34, namely SP6.34A, SP6.34G and SP6.34C with CoV2-S by flow cytometry. These point mutants were chosen to either stabilize (SP6.34C) or destabilize (SP6.34A, SP6.34G) the putative apical stem structure (<bold>
<xref ref-type="fig" rid="F1">Fig. 1j</xref>
</bold>). However, all point mutants revealed severely diminished binding to CoV2-S, whereas binding of SP6.34A was still detectable (<bold>
<xref ref-type="fig" rid="F1">Fig. 1i</xref>
</bold>), albeit to a much lesser extent than SP6. Mutating the positions equivalent to SP6.34C in the parental aptamer SP6, yielding SP6C, also abolishes CoV2-S binding (<bold>
<xref ref-type="fig" rid="F1">Fig. 1k</xref>
</bold>). To conclude the characterization of SP6, the impact of mono- and divalent ions on CoV2-S binding was assessed by flow cytometry of both, the parental and minimal variant of the aptamer. These studies reveal that the binding of SP6 to CoV2-S is sensitive towards the presence of K<sup>+</sup> and strongly depends on Mg<sup>2+</sup>-ions (<bold>
<xref ref-type="fig" rid="F1">Fig. 1k</xref>
</bold>). The binding of the parental aptamer SP6 to CoV2-S was maintained in the absence of K<sup>+</sup>-ions, whereas the interaction of the minimal variant SP6.34 was found to be reduced by about 50% compared to its level obtained in PBS (<bold>
<xref ref-type="fig" rid="F1">Fig. 1k</xref>
</bold>). These data indicate that K<sup>+</sup>-ions are most likely required for supporting structure formation of the aptamer, which is more pronounced in the truncated variant than in the parental full-length aptamer, but not essential for CoV2-S binding.</p>
</sec>
<sec id="S4">
<title>Aptamers selected for the RBD do not interact with CoV2-S</title>
<p id="P6">We also performed automated selection procedures to target the isolated RBD of Cov2-S (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 3</xref>
</bold>). Conventional automated selection conditions, as applied targeting CoV2-S (<bold>
<xref ref-type="fig" rid="F1">Fig. 1</xref>
</bold>), resulted in strong overamplification during the PCR step (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 3a</xref>
</bold>), which could be decreased by reducing the amount of target (10% compared to the conventional approach, <bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 3b</xref>
</bold>) or by adding heparin as a competitor during the incubation step of the selection procedure (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 3c</xref>
</bold>). Interaction analysis of the obtained DNA libraries from the selection cycles in which no or very low overamplification was observed, i.e. cycle 6 of the conventional procedure (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 3a</xref>
</bold>), cycle 9 when less target was used (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 3b</xref>
</bold>), and cycle 8 when heparin was added (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 3c</xref>
</bold>), revealed enrichment of RBD binding species in all selections (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 3d</xref>
</bold>). However, none of the enriched RBD-binding libraries interacted with full-length CoV2-S comprising the complete extracellular domain (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 3d</xref>
</bold>). The starting library, used as negative control, neither bound to RBD nor to CoV2-S, whereas the library enriched for CoV2-S (R12 CoV2-S, <bold>
<xref ref-type="fig" rid="F1">Fig. 1a</xref>
</bold>), used as positive control, showed binding to CoV2-S as expected (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 3d</xref>
</bold>). Of note, library R12 CoV2-S also revealed interaction with RBD, although to a lesser extent than to CoV2-S (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 3d</xref>
</bold>). Therefore, we decided to use the library R12 CoV2-S to conduct three additional selection cycles (cycles 13-15) enriching for those species that bind predominantly to RBD instead of other domains of CoV2-S, that are presumably targeted by SP5, SP6, and SP7 (<bold>
<xref ref-type="fig" rid="F1">Fig. 1h</xref>
</bold>). We again used the conventional selection approach (cycles 13-15, <bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 3e</xref>
</bold>) and a selection variant with less (10%) RBD than in the preceding selection (cycles 13*-15*, <bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 3e</xref>
</bold>). In both cases overamplification was observed from cycle 13/13* on, although less pronounced as during the <italic>de novo</italic> selection targeting RBD under previously applied selection conditions (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 3a</xref>
</bold>). Both enriched libraries (R15/R15*) showed binding to RBD but no interaction with CoV2-S (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 3f</xref>
</bold>). Next-generation sequencing of the obtained libraries revealed two strongly enriched distinct families (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 3g-i</xref>
</bold>, <bold>Supporting Tables 2,3</bold>). We chose four representative sequences, RBD1-4, and performed interaction analysis. These experiments were found to be in-line with the observations obtained with the enriched libraries, i.e. the sequences bound to RBD (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 3j</xref>
</bold>) but not CoV2-S (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 3k</xref>
</bold>). Despite RBD4, which was found at elevated copy numbers in selection cycle 6 of the selection targeting CoV2-S but declining thereafter, all RBD binding sequences only increased in copy numbers when the target changed from CoV2-S to RBD in selection cycles 13-15 (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 3l</xref>
</bold>) and 13* to 15* (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 3m</xref>
</bold>). These data indicate that targeting RBD of CoV2-S with DNA libraries, in our hands, was not productive in yielding aptamers interacting with the full-length extracellular domain of CoV2-S protein <italic>in vitro</italic>.</p>
</sec>
<sec id="S5">
<title>SP6 inhibits viral infection independent of the interaction of CoV2-S with ACE2</title>
<p id="P7">We next performed pulldown experiments to further characterize and verify the interaction of SP6 with CoV2-S (<bold>
<xref ref-type="fig" rid="F2">Fig 2a</xref>
</bold>). In these experiments, biotinylated SP6 or SP6C were incubated with the respective protein and the complexes were collected by adding streptavidin coated magnetic beads. After washing, the remaining proteins were analyzed by SDS-PAGE and Coomassie staining of the gel. Aliquots were taken and analyzed prior to the incubation with the magnetic beads (input, <bold>
<xref ref-type="fig" rid="F2">Fig. 2a</xref>
</bold>), from the supernatant after incubation with the magnetic beads (unbound, <bold>
<xref ref-type="fig" rid="F2">Fig. 2a</xref>
</bold>) and from the bead/aptamer bound fraction (eluate, <bold>
<xref ref-type="fig" rid="F2">Fig. 2a</xref>
</bold>). SP6 revealed binding to CoV2-S (<bold>
<xref ref-type="fig" rid="F2">Fig. 2a</xref>
</bold>, eluate, lane 2) but not to CoV-S (eluate, lane 6) nor to ACE2 (eluate, lane 4) or the unrelated control protein Nek7 (eluate, lane 5). In this experiment, SP6C showed weak binding to CoV2-S (<bold>
<xref ref-type="fig" rid="F2">Fig. 2a</xref>
</bold>, eluate, lane 1). In agreement with the results obtained by flow cytometry (<bold>
<xref ref-type="fig" rid="F1">Fig. 1h</xref>
</bold>) binding of SP6 to CoV2-S was not reduced even in the presence of a fivefold molar excess of RBD (<bold>
<xref ref-type="fig" rid="F2">Fig.2a</xref>
</bold>, eluate, lane 3).</p>
<p id="P8">As SP6 appears not to interact with the RBD of CoV2-S, we investigated whether SP6 has an impact on the interaction of CoV2-S and ACE2. To this end, His-tagged CoV2-S was pulled by Ni-NTA magnetic beads and the co-pulldown of untagged ACE2 (ACE2ΔHis) was analyzed in the presence or absence of SP6 (<bold>
<xref ref-type="fig" rid="F2">Fig. 2b</xref>
</bold>). As before, input, unbound and eluate fractions were analyzed by SDS-PAGE and Coomassie staining. Whereas the interaction between CoV2-S and ACE2 was abolished by the RBD-binding control nanobody VHH E (<bold>
<xref ref-type="fig" rid="F2">Fig. 2b</xref>
</bold>, eluate, lane 4), SP6 did not affect this interaction (eluate, lane 3). Densitometric analysis of the respective bands resulted in ACE2:Cov2-S ratios of 0.18 and 0.16 in the absence (eluate, lane 1) or presence (eluate, lane 3) of SP6, respectively.</p>
<p id="P9">Having shown SP6 interacts with CoV2-S without interfering with complex formation with its cellular receptor ACE2, we next studied the impact of SP6 on viral infection. To address this question, we used the established VSV-ΔG*-based pseudotype system<sup>
<xref rid="R17" ref-type="bibr">17</xref>,</sup>
<sup>
<xref ref-type="bibr" rid="R18">18</xref>
</sup> and generated Cov2-S and VSV-G pseudotyped virus particles. The interaction of SP6 with the CoV2-S pseudotyped virus was verified by an enzyme-linked oligonucleotide assay (ELONA).<sup>
<xref rid="R19" ref-type="bibr">19</xref>
</sup> In this experiment, the CoV2-S protein or the CoV2-S pseudotyped virus were captured by a nanobody binding to the RBD of CoV2-S and after washing the bound protein or pseudovirus particles were detected by adding biotinylated SP6, streptavidin-horse radish peroxidase (HRP) conjugates and its substrate 2,2′-Azino-di(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 4</xref>
</bold>). We observed a concentration dependent increase in signal when SP6 and SP6.34 were used for detection, but not when employing SP6C and SP6.34C (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 4a</xref>
</bold>). Likewise, SP6 but not SPC6C detected the CoV2-S pseudotyped virus. The VSV-G pseudotype was not detected demonstrating the specificity of the assay (<bold>
<xref ref-type="fig" rid="F2">Fig 2c</xref>
</bold>). Next, ACE2-expressing Vero E6 cells were infected with Cov2-S or VSV-G pseudotyped virus particles, which had been pre-incubated with SP6 or SP6C (<bold>
<xref ref-type="fig" rid="F2">Fig. 2c</xref>
</bold>). Pseudotype particle numbers were adjusted to result in infection rates between 8 % and 10 % for the aptamer-untreated pseudotypes (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 4b,c</xref>
</bold>). This infection rate was chosen to prevent multiple infections of a single cell precluding reliable measurements. SP6 showed a concentration-dependent reduction of infection of Vero E6 cells by the CoV2-S pseudotype virus (<bold>
<xref ref-type="fig" rid="F2">Fig. 2d</xref>
</bold>, <bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 4b,c</xref>
</bold>). In contrast, the infection of the VSV-G pseudotype was not affected (<bold>
<xref ref-type="fig" rid="F2">Fig. 2d</xref>
</bold>). These results demonstrate the dependence of the inhibitory effect of SP6 on the presence of CoV2-S on the viral particles and exclude unspecific effects on the infection process of the VSV-G vector. The presence of SP6C also led to some reduction of infection which, however, did not reach statistical significance. The seeming discrepancy to the lack of binding of SP6C to CoV2-S in the binding assay (<bold>
<xref ref-type="fig" rid="F1">Fig. 1k</xref>
</bold>) or the ELONA (<bold>
<xref ref-type="fig" rid="F2">Fig. 2c</xref>
</bold>) is explained by the higher concentrations of SP6C used in the infection assay. In addition, unmodified SP6 (as used in the infection assay) shows stronger binding to CoV2-S than the 5´-modified versions (<bold>
<xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 2c</xref>
</bold>) and this can also be assumed for SP6C. The slight inhibitory effect of SP6C is in-line with its observed weak interaction with CoV2-S in the pulldown assay (<bold>
<xref ref-type="fig" rid="F2">Fig. 2a</xref>
</bold>).</p>
<p id="P10">Whereas ACE2 is the most important receptor for CoV2-S, at least two co-receptors are known to contribute to CoV2-S binding to target cells, heparan sulfate and neuropilin-1.<sup>
<xref rid="R20" ref-type="bibr">20</xref>,</sup>
<sup>
<xref ref-type="bibr" rid="R21">21</xref>
</sup> Therefore, we investigated whether SP6 affected binding of CoV2-S pseudotyped particles to cells even if it did not inhibit CoV2-S binding to ACE2. For this purpose, VSV-ΔG* was pseudotyped with CoV2-S carrying a HiBiT tag at the C-terminus. Vero E6 cells were incubated with these particles and bound virus was quantified by NanoBiT reconstitution (<bold>
<xref ref-type="fig" rid="F2">Fig 2e</xref>
</bold>). Whereas the known inhibitor heparin<sup>
<xref rid="R22" ref-type="bibr">22</xref>
</sup> reduced binding of CoV2-S pseudotyped particles, neither SP6 nor SP6C had an effect on binding. These data show that SP6 reduces pseudovirus infection by interfering with a process occurring after binding of the pseudovirus to cells.</p>
</sec>
</sec>
<sec id="S6" sec-type="discussion">
<title>Discussion</title>
<p id="P11">In conclusion, we describe the DNA aptamer SP6 binding to CoV2-S and with the potential to inhibit SARS-CoV-2 infection. A remarkable and unexpected feature of SP6 is that its inhibitory effect does not result from interfering with the interaction of CoV2-S with ACE2. This feature distinguishes the mode of action of SP6 from that of CoV2-S targeting antibodies. Currently, the overwhelming majority of these antibodies bind to the RBD of CoV2-S<sup>
<xref rid="R6" ref-type="bibr">6</xref>-</sup>
<sup>
<xref rid="R11" ref-type="bibr">11</xref>
</sup> and prevent ACE2 interaction by either directly competing with ACE2 for binding<sup>
<xref rid="R6" ref-type="bibr">6</xref>-</sup>
<sup>
<xref rid="R10" ref-type="bibr">10</xref>
</sup> or by stabilizing an ACE2 binding-incompetent conformation<sup>
<xref rid="R11" ref-type="bibr">11</xref>
</sup>. Antibodies not binding to RBD but to the N-terminal domain of CoV2-S have also been shown to prevent interaction of CoV2-S with ACE2 although by an yet unknown mechanism.<sup>
<xref rid="R10" ref-type="bibr">10</xref>
</sup> To our knowledge, neutralizing antibodies targeting the S2 domain have not yet been described. At present, the molecular mechanism by which SP6 inhibits viral infection is unknown. As the binding of CoV2-S pseudotypes to cells is not affected, we conclude that a step occurring after binding must be impeded. This could involve preventing S2´ cleavage or destabilizing the prefusion conformation of the spike protein. The latter mechanism has been shown to lead to viruses bearing spike proteins in the postfusion conformation and has been reported for an antibody neutralizing SARS-CoV.<sup>
<xref rid="R23" ref-type="bibr">23</xref>
</sup> This antibody, however, binds to the RBD. We anticipate that the elucidation of the mechanism by which SP6 inhibits infection will provide insight into how CoV2-S triggers fusion of the viral and host cell membranes.</p>
<p id="P12">There is an increasing number of currently reported mutations in SARS-CoV-2<sup>
<xref rid="R9" ref-type="bibr">9</xref>
</sup>, among which the most recent example is the apparently faster spreading lineage VUI-202012/01, also named B.1.1.7.<sup>
<xref rid="R24" ref-type="bibr">24</xref>
</sup> This variant shows several mutations in the RBD resulting in escape of binding to some antibodies. Since more escape mutations in the RBD can be expected to further arise in the future, RBD-independent modalities to prevent infection, as revealed by SP6, are of relevance and need to be investigated.</p>
<p id="P13">SP6 might be further optimized to increase potency. For example, homo- or heterovalent multimers could be engineered by combining SP6 with itself or aptamers (or other ligands) binding to different CoV2-S domains, a strategy employed previously to gain very potent thrombin inhibitors.<sup>
<xref rid="R25" ref-type="bibr">25</xref>,</sup>
<sup>
<xref ref-type="bibr" rid="R26">26</xref>
</sup> Indeed, di- or trimerization of CoV2-S antibodies has been shown to increase their potency.<sup>
<xref rid="R11" ref-type="bibr">11</xref>,</sup>
<sup>
<xref ref-type="bibr" rid="R27">27</xref>
</sup> The automated selection process enables the rapid generation of aptamers, for example for mutated proteins of SARS-CoV-2 lineages that escape treatment regimens by aptamers, antibodies, or other active pharmaceutical ingredients. Likewise, re-selection strategies to adapt SP6 towards mutations are also possible. In addition to these features, aptamers provide means to develop antigen tests, exemplified by the presented SP6-based ELONA data. The ease by which aptamers can be synthesized, their low batch-to-batch variations and long shelf lives predestines SP6 for various diagnostic and treatment options, e.g., as inhalation spray.</p>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supporting Information</label>
<media xlink:href="EMS109236-supplement-Supporting_Information.pdf" mimetype="application" mime-subtype="pdf" id="N66562" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S7">
<title>Acknowledgement</title>
<p>This work has been made possible by funds from the Federal Ministry of Education and (BMBF, 01KI20154 to MF and GM) and by the German Research Council (DFG, MA3442/7-1 to GM). We thank Dr. F.-I. Schmidt and Dr. P.-A. König (Core Facility Nanobodies, Medical Faculty, University of Bonn) for providing the RBD nanobody and Prof. J. Schultze for performing NGS (University of Bonn/DZNE). We are grateful to Dr. G. Zimmer (Institute of Virology and Immunology, Mittelhäusern, Switzerland) for providing the VSV-ΔG* and to Prof. J.S. McLellan (The University of Texas at Austin, USA) for providing the plasmid for CoV2-S expression.</p>
</ack>
<fn-group>
<fn fn-type="con" id="FN1">
<p id="P14">
<bold>Author contribution</bold>
</p>
<p id="P15">AS developed the cellular binding and partly executed the cellular binding and infection assays, constructed the pseudotype viruses and wrote the manuscript. AW performed sequence analysis of the enriched libraries and conducted interaction analysis of the DNA libraries, aptamers and their variants. MB conducted infection and binding experiments. SB performed the automated selection experiments. VF expressed and purified proteins and performed the pulldown experiments. MF supervised experiments, discussed results and wrote the manuscript. GM conceived and designed the study, supervised and discussed results and wrote the manuscript. All authors have read and commented on the manuscript.</p>
</fn>
<fn id="FN2" fn-type="conflict">
<p id="P16">
<bold>Competing interests</bold>
</p>
<p id="P17">AS, AW, SB, VF, MF and GM are listed as inventors on a pending patent application on the aptamers described in this study.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hatmal</surname>
<given-names>MM</given-names>
</name>
<etal/>
</person-group>
<article-title>Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS- CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2</article-title>
<source>Cells</source>
<year>2020</year>
<volume>9</volume>
<fpage>2638</fpage>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benton</surname>
<given-names>DJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion</article-title>
<source>Nature</source>
<year>2020</year>
<volume>588</volume>
<fpage>327</fpage>
<lpage>330</lpage>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Distinct conformational states of SARS-CoV-2 spike protein</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>1586</fpage>
<lpage>1592</lpage>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robbiani</surname>
<given-names>DF</given-names>
</name>
<etal/>
</person-group>
<article-title>Convergent antibody responses to SARS-CoV-2 in convalescent individuals</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>437</fpage>
<lpage>442</lpage>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnes</surname>
<given-names>CO</given-names>
</name>
<etal/>
</person-group>
<article-title>Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies</article-title>
<source>Cell</source>
<year>2020</year>
<volume>182</volume>
<fpage>828</fpage>
<lpage>842.e16</lpage>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>A human monoclonal antibody blocking SARS-CoV-2 infection</article-title>
<source>Nat Commun</source>
<year>2020</year>
<volume>11</volume>
<fpage>22516</fpage>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ju</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>Human neutralizing antibodies elicited by SARS-CoV-2 infection</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>115</fpage>
<lpage>119</lpage>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>120</fpage>
<lpage>124</lpage>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>450</fpage>
<lpage>456</lpage>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huo</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2</article-title>
<source>Nat Struct Mol Biol</source>
<year>2020</year>
<volume>27</volume>
<fpage>846</fpage>
<lpage>854</lpage>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schoof</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike</article-title>
<source>Science</source>
<year>2020</year>
<volume>370</volume>
<fpage>1473</fpage>
<lpage>1479</lpage>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<etal/>
</person-group>
<article-title>The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity</article-title>
<source>Cell</source>
<year>2020</year>
<volume>182</volume>
<fpage>1284</fpage>
<lpage>1294.e9</lpage>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Breuers</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bryant</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Legen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Robotic assisted generation of 2‘-deoxy-2’-fluoro- modifed RNA aptamers - High performance enabling strategies in aptamer selection</article-title>
<source>Methods</source>
<year>2019</year>
<volume>161</volume>
<fpage>3</fpage>
<lpage>9</lpage>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wrapp</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title>
<source>Science</source>
<year>2020</year>
<volume>367</volume>
<fpage>1260</fpage>
<lpage>1263</lpage>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsieh</surname>
<given-names>CL</given-names>
</name>
<etal/>
</person-group>
<article-title>Structure-based design of prefusion-stabilized SARS-CoV-2 spikes</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>1501</fpage>
<lpage>1505</lpage>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weber</surname>
<given-names>AM</given-names>
</name>
<etal/>
</person-group>
<article-title>A blue light receptor that mediates RNA binding and translational regulation</article-title>
<source>Nat Chem Biol</source>
<year>2019</year>
<volume>15</volume>
<fpage>1085</fpage>
<lpage>1092</lpage>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berger Rentsch</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon</article-title>
<source>PLoS ONE</source>
<year>2011</year>
<volume>6</volume>
<comment>e25858</comment>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zettl</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>
<article-title>Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation- Defective Vesicular Stomatitis Virus Pseudotypes</article-title>
<source>Vaccines (Basel)</source>
<year>2020</year>
<volume>8</volume>
<fpage>386</fpage>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drolet</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Moon-McDermott</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Romig</surname>
<given-names>TS</given-names>
</name>
</person-group>
<article-title>An enzyme-linked oligonucleotide assay</article-title>
<source>Nat Biotechnol</source>
<year>1996</year>
<volume>14</volume>
<fpage>1021</fpage>
<lpage>1025</lpage>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clausen</surname>
<given-names>TM</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2</article-title>
<source>Cell</source>
<year>2020</year>
<volume>183</volume>
<fpage>1043</fpage>
<lpage>1057.e15</lpage>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cantuti-Castelvetri</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity</article-title>
<source>Science</source>
<year>2020</year>
<volume>370</volume>
<fpage>856</fpage>
<lpage>860</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tandon</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives</article-title>
<source>J Virol</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1128/JVI.01987-20</pub-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<etal/>
</person-group>
<article-title>Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion</article-title>
<source>Cell</source>
<year>2019</year>
<volume>176</volume>
<fpage>1026</fpage>
<lpage>1039.e15</lpage>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<article-title>Microsoft Word-Report 1COG-UK 20 December 2020_SARS-CoV-2 Mutations_final docx</article-title>
<year>2020</year>
<fpage>1</fpage>
<lpage>9</lpage>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Müller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wulffen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pötzsch</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Multidomain targeting generates a high-affinity thrombin-inhibiting bivalent aptamer</article-title>
<source>Chembiochem</source>
<year>2007</year>
<volume>8</volume>
<fpage>2223</fpage>
<lpage>2226</lpage>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Molecular assembly for high-performance bivalent nucleic acid inhibitor</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>2008</year>
<volume>105</volume>
<fpage>5664</fpage>
<lpage>5669</lpage>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bracken</surname>
<given-names>CJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2</article-title>
<source>Nat Chem Biol</source>
<year>2021</year>
<volume>17</volume>
<fpage>113</fpage>
<lpage>121</lpage>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tolle</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Preparation of SELEX Samples for Next-Generation Sequencing</article-title>
<source>Methods Mol Biol</source>
<year>2016</year>
<volume>1380</volume>
<fpage>77</fpage>
<lpage>84</lpage>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zuker</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Mfold web server for nucleic acid folding and hybridization prediction</article-title>
<source>Nucleic Acids Res</source>
<year>2003</year>
<volume>31</volume>
<fpage>3406</fpage>
<lpage>3415</lpage>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>KK</given-names>
</name>
</person-group>
<article-title>Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>1261</fpage>
<lpage>1265</lpage>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<fpage>271</fpage>
<lpage>280.e8</lpage>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<title>Selection of DNA aptamers binding to CoV2-S.</title>
<p>
<bold>a)</bold> Interaction analysis of the enriched DNA library from selection cycle 1 (R1) and 12 (R12) in respect to empty beads, CoV2-S, Erk2 and Dectin. <bold>b)</bold> Amount of unique sequences in the DNA populations from selection cycle 1-12 and the starting library (SL). c) Fraction of sequences in the DNA population from selection cycle 1-12 and the starting library (SL) sharing the indicated copy numbers. <bold>d)</bold> Frequency of sequences throughout the DNA population from selection cycles 0-12 belonging to the sequence families 8, 13, 22, 29, or 30. See also <xref ref-type="supplementary-material" rid="SD1">Supporting Fig. 1d</xref>. <bold>e)</bold> Frequency of representative sequences belonging to one of the families from (<bold>d)</bold>. SP1 (Fam 30), SP2 (Fam 29), SP3 (Fam 22), SP4 (Fam 13), SP5-7 (Fam 8). <bold>f)</bold> Interaction analysis of aptamers SP1-7, the starting library (SL) and DNA from selection cycle 12 (R12) with CoV2-S. SP5sc: scrambled control sequence with identical nucleotides as SP5 but with different primary structure. g) Sequence motif of family 8 and assignment of aptamers SP5-7. <bold>h)</bold> Interaction analysis of the scrambled sequence SP5sc and aptamers SP5-7 with CoV2-S, RBD, ACE2, and CoV-S. <bold>i)</bold> Interaction analysis of SP6 and shortened variants and defined single point mutants thereof (<bold>j</bold>). <bold>k)</bold> Interaction analysis of SP6, SP6.34 and the respective control aptamers SP6C (see <xref ref-type="supplementary-material" rid="SD1">supporting Fig. 2d</xref>) and SP6.34C (<bold>j</bold>) with CoV2-S in the absence and presence of Mg<sup>2+</sup>-ions or K<sup>+</sup>-ions. a,f, h,i, and k: N=2, mean +/- SD.</p>
</caption>
<graphic xlink:href="EMS109236-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<title>RBD independent inhibition of CoV2-S pseudovirus infection.</title>
<p>
<bold>a)</bold> Pulldown analysis of SP6 binding specificity. ΔST indicates constructs lacking the StrepTag. <bold>b)</bold> Pulldown analysis of CoV2-S ACE2 interaction. ΔHis indicates lack of His tag. <bold>c)</bold> ELONA of S protein and SARS-CoV-2-S pseudotype virus. <bold>d)</bold> SARS-CoV-2-S pseudovirus infection. n=5, mean +/- SD, *** p&lt;0.001, ** p&lt;0.01, * p&lt;0.05. <bold>e)</bold> SARS-CoV-2-S pseudovirus binding. n=8, mean +/- SD *** p&lt;0.001</p>
</caption>
<graphic xlink:href="EMS109236-f002"/>
</fig>
<table-wrap id="T1" position="float" orientation="portrait">
<label>Table 1</label>
<caption>
<title>Kinetic properties of the aptamers SP5, SP6 and SP7 measured by surface plasmon resonance.</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="left" valign="middle">Sequence</th>
<th align="left" valign="middle">Condition</th>
<th align="left" valign="middle">k<sub>a</sub> (10<sup>4</sup>M<sup>-1</sup>s<sup>-1</sup>)</th>
<th align="left" valign="middle">k<sub>d</sub>(10<sup>4</sup>s<sup>-1</sup>)</th>
<th align="left" valign="middle">K<sub>D</sub>(nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" style="background-color:#d6d7d6">SP5</td>
<td align="left" valign="top" style="background-color:#d6d7d6">37°C</td>
<td align="left" valign="top" style="background-color:#d6d7d6">1 ± 0.2</td>
<td align="left" valign="top" style="background-color:#d6d7d6">37 ± 36</td>
<td align="left" valign="top" style="background-color:#d6d7d6">9.2 ± 7.9</td>
</tr>
<tr>
<td align="left" valign="top">SP6</td>
<td align="left" valign="top">37°C</td>
<td align="left" valign="top">2.1 ± 0.6</td>
<td align="left" valign="top">4.5 ± 1.9</td>
<td align="left" valign="top">21 ± 4.6</td>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#d6d7d6">SP7</td>
<td align="left" valign="top" style="background-color:#d6d7d6">37°C</td>
<td align="left" valign="top" style="background-color:#d6d7d6">1.5 ± 0.4</td>
<td align="left" valign="top" style="background-color:#d6d7d6">2.9 ± 1.2</td>
<td align="left" valign="top" style="background-color:#d6d7d6">18.9 ± 5.5</td>
</tr>
<tr>
<td align="left" valign="top">SP5</td>
<td align="left" valign="top">25°C</td>
<td align="left" valign="top">1.19 ± 0.1</td>
<td align="left" valign="top">1.74 ± 0.01</td>
<td align="left" valign="top">14.7 ± 0.8</td>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#d6d7d6">SP6</td>
<td align="left" valign="top" style="background-color:#d6d7d6">25°C</td>
<td align="left" valign="top" style="background-color:#d6d7d6">2.5 ± 0.3</td>
<td align="left" valign="top" style="background-color:#d6d7d6">3.4 ± 0.2</td>
<td align="left" valign="top" style="background-color:#d6d7d6">13.9 ± 0.6</td>
</tr>
<tr>
<td align="left" valign="top">SP7</td>
<td align="left" valign="top">25°C</td>
<td align="left" valign="top">1.3 ± 0.2</td>
<td align="left" valign="top">1.7 ± 0.7</td>
<td align="left" valign="top">13.1 ± 3.8</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
